Six Weeks Too Late? Praxbind Gets 2017 Medicare Boost But Not AndexXa

User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.

Portola Pharmaceuticals Inc. is on the cusp of FDA action on its universal anticoagulant reversal agent AndexXa (andexanet alfa) with a user fee date of Aug. 17. But should it win that approval, it will have to wait until next year to gain bonus Medicare payments as an important new technology for hospital patients.

Both AndexXa and Boehringer Ingelheim GMBH's Praxbind (idarucizumab), a reversal agent specifically for Pradaxa (dabigatran), were under consideration for...

More from Market Access

More from Pink Sheet